The COVID pandemic likely began when the virus jumped from animals to humans, and didn’t start in a lab. But false narratives ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the ...

(Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The ...

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group ...

SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVIDSPEAR Study Group ...

WALTHAM, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced full Phase 1/2 clinical data for VYD2311, a next-generation monoclonal antibody (mAb) candidate ...

Invivyd reports positive Phase 1/2 results for VYD2311, showing safety, long half-life, and potential for effective COVID-19 prevention. Quiver AI Summary Invivyd, Inc. announced promising results ...

Invivyd, Inc. (NASDAQ:IVVD – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Invivyd in a research report issued on Wednesday ...

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2.

About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a ...